Research for Multiple Myeloma

The multiple myeloma program at Mount Sinai aims to cure myeloma and prevent it from developing in the first place. Our bench-to-bedside precision medicine approach integrates advances in genomics and immunotherapy to change the landscape for all patients, including those with resistant disease and those with pre-myeloma conditions such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM). We are investigating novel agents such as monoclonal antibodies for relapsed and refractory disease, and immunotherapy initiatives such as CAR-T cell therapy and personalized vaccine-based preventive strategies. Our research focus includes:

Mount Sinai Expertise

Our patients benefit from our in-depth collaborations with expert scientists across the Mount Sinai Health System. Some of the institutes and laboratories that we partner with are: